GW Pharmaceuticals PLC- (GWPH) Set to Announce Quarterly Earnings on Tuesday

GW Pharmaceuticals PLC- (NASDAQ:GWPH) is set to issue its quarterly earnings data after the market closes on Tuesday, November 27th. Analysts expect the company to announce earnings of ($2.35) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Shares of NASDAQ:GWPH opened at $124.05 on Monday. The firm has a market cap of $3.74 billion, a price-to-earnings ratio of -17.85 and a beta of 2.25. GW Pharmaceuticals PLC- has a 12-month low of $105.12 and a 12-month high of $179.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.67 and a quick ratio of 8.21.

GWPH has been the subject of a number of research reports. BidaskClub lowered shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. ValuEngine lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Cantor Fitzgerald reduced their price objective on shares of GW Pharmaceuticals PLC- from $235.00 to $211.00 and set an “overweight” rating for the company in a research note on Wednesday, August 8th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. Finally, Stifel Nicolaus started coverage on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, August 14th. They issued a “buy” rating and a $181.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- currently has an average rating of “Buy” and a consensus target price of $187.63.

A hedge fund recently raised its stake in GW Pharmaceuticals PLC- stock. Bank of New York Mellon Corp increased its position in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 134.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,053 shares of the biopharmaceutical company’s stock after acquiring an additional 7,496 shares during the quarter. Bank of New York Mellon Corp’s holdings in GW Pharmaceuticals PLC- were worth $1,822,000 at the end of the most recent quarter. Institutional investors and hedge funds own 71.26% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first posted by WKRB News and is the property of of WKRB News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

See Also: Earnings Per Share

Earnings History for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with's FREE daily email newsletter.

Leave a Reply